drugset
drugset / Trial / NCT06087458

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT06087458 ↗

Phase 1/2 Recruiting 60 enrolled Perceive Biotherapeutics, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Timeline

Start
2023-06-21
Primary completion
2027-06
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject VOY-101 Unknown — Intravitreal

Indications

diffuse secondary choroid atrophy dry age related macular degeneration